Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
PT Siloam International Hospitals Tbk (SILO.JK)
Tangerang, JK, ID
PT Siloam International Hospitals Tbk operates hospitals and clinics in Indonesia. The company offers general, pre-marital, and lite checkups; male and female screenings; heart, kidney, and cancer screenings; visa application and preemployment screenings; and vaccine and genomic testing services. It also provides diagnostic services, including laboratory and radiology checks; home services; COVID-19 tests; radiation therapy; and teleconsultation services. In addition, it offers services in the areas of andrology, anesthesiology, and arrythmia; cardiothoracic, digestive, general, neuro, pediatric, plastic, and vascular surgery; cardiology, cardiovascular emergency and intensive care, cardiovascular imaging, pediatric cardiology and congenital heart diseases, and preventive cardiology and cardiac rehabilitation; clinical nutrition and psychology; medical acupuncture and laboratory; dermatology, venereology, and aesthetics; and echocardiography, internal medicine, interventional cardiology, neurology, nuclear medicine, obstetrics and gynecologist, occupational medicine, ophthalmology, orthopedic and traumatology, otorhinolaryngology, physical medicine and rehabilitation, pulmonology, radiation oncology, radiology, sports medicine, and urology. Further, it engages in trading, development, mining, agriculture, land transportation, printing, plantation, forestry, electrical, mechanical, engineering, construction, and real estate businesses; computer programming; software publishing and retail trading; provision of management consulting, retail, professional, and scientific and technical; web portal and/or digital platform business; workshops; leasing; wholesale trade; IT; and social services. The company was formerly known as PT Sentralindo Wirasta. PT Siloam International Hospitals Tbk was founded in 1996 and is headquartered in Tangerang, Indonesia. PT Siloam International Hospitals Tbk operates as a subsidiary of Sight Investment Company Pte. Limited.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.26% | -2.07% | -5.60% | -11.94% | -4.07% | -10.27% | +0.85% | +43.03% | +126.11% | +90.64% | +100.03% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 5 | -1 |
| Hold | 3 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%+5.2% Q1'26: +7.9% (vs Q1'25)
-
EPS growth Medical - Care Facilities: +19.2%+23.8% ★ Q1'26: +13.8% (vs Q1'25)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%+9.1% Q1'26: +2.7% (vs Q1'25)
-
EBIT margin Medical - Care Facilities: +11.3%+13.0% ★ Q1'26: +12.5% (vs Q1'25)
-
ROIC Medical - Care Facilities: +6.8%+12.1% ★ Q1'26: +11.3% (vs Q1'25)
-
Share dilution Medical - Care Facilities: +0.0%-0.4% ★ Q1'26: -0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×0.61× ★ Q1'26: 0.78× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 6 EPS Ana. |
Dec 2027 7 Rev. Ana. 7 EPS Ana. |
Dec 2028 4 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
4.14T
est: 4.11T (+1.0%)
|
5.17T
est: 5.16T (+0.2%)
|
5.85T
est: 5.98T (-2.2%)
|
5.96T
est: 5.96T (0.0%)
|
7.02T
est: 6.63T (+5.8%)
|
7.11T
est: 6.82T (+4.3%)
|
9.38T
est: 7.89T (+18.8%)
|
9.52T
est: 8.30T (+14.7%)
|
11.19T
est: 11.93T (-6.2%)
|
12.21T
est: 12.45T (-1.9%)
|
12.85T
est: 12.75T (+0.8%)
|
13.35T
12.97T – 13.72T
+4.7% YoY
|
14.76T
13.85T – 15.41T
+10.6% YoY
|
15.25T
15.13T – 15.38T
+3.4% YoY
|
| EBITDA |
495.03B
est: 838.16B (-40.9%)
|
581.34B
est: 1.05T (-44.8%)
|
626.93B
est: 1.22T (-48.6%)
|
705.41B
est: 1.22T (-42.1%)
|
448.72B
est: 1.35T (-66.9%)
|
1.21T
est: 1.39T (-13.1%)
|
1.99T
est: 1.61T (+23.3%)
|
2.01T
est: 1.69T (+18.9%)
|
2.69T
est: 2.53T (+6.4%)
|
2.28T
est: 2.64T (-13.7%)
|
2.70T
est: 2.71T (-0.3%)
|
2.83T
2.75T – 2.91T
+4.7% YoY
|
3.13T
2.94T – 3.27T
+10.6% YoY
|
3.24T
3.21T – 3.26T
+3.4% YoY
|
| EBIT |
158.07B
est: 451.74B (-65.0%)
|
221.70B
est: 567.38B (-60.9%)
|
219.29B
est: 657.71B (-66.7%)
|
207.51B
est: 656.41B (-68.4%)
|
-122.00B
est: 729.66B (-116.7%)
|
401.82B
est: 749.96B (-46.4%)
|
1.04T
est: 868.79B (+19.5%)
|
1.05T
est: 913.28B (+15.2%)
|
1.75T
est: 1.49T (+17.7%)
|
1.42T
est: 1.55T (-8.7%)
|
1.67T
est: 1.59T (+4.9%)
|
1.66T
1.62T – 1.71T
+4.7% YoY
|
1.84T
1.73T – 1.92T
+10.6% YoY
|
1.90T
1.89T – 1.92T
+3.4% YoY
|
| Net Income |
70.40B
est: 122.24B (-42.4%)
|
85.90B
est: 144.96B (-40.7%)
|
93.57B
est: 109.75B (-14.7%)
|
16.18B
est: 33.57B (-51.8%)
|
-333.00B
est: 65.21B (-610.7%)
|
116.16B
est: 2.67B (+4,254.2%)
|
674.12B
est: 659.46B (+2.2%)
|
696.50B
est: 588.58B (+18.3%)
|
1.21T
est: 1.02T (+18.5%)
|
902.15B
est: 1.13T (-20.2%)
|
1.11T
est: 1.02T (+9.3%)
|
1.18T
863.17B – 1.38T
+15.9% YoY
|
1.34T
916.47B – 1.83T
+13.2% YoY
|
1.48T
665.60B – 2.33T
+10.6% YoY
|
| SGA |
373.33B
est: 303.89B (+22.8%)
|
475.38B
est: 381.68B (+24.5%)
|
494.44B
est: 442.45B (+11.8%)
|
590.78B
est: 441.57B (+33.8%)
|
670.57B
est: 490.85B (+36.6%)
|
454.96B
est: 504.50B (-9.8%)
|
747.38B
est: 584.44B (+27.9%)
|
716.89B
est: 614.37B (+16.7%)
|
827.38B
est: 925.27B (-10.6%)
|
942.86B
est: 965.74B (-2.4%)
|
1.05T
est: 989.40B (+6.2%)
|
1.04T
1.01T – 1.06T
+4.7% YoY
|
1.15T
1.07T – 1.20T
+10.6% YoY
|
1.18T
1.17T – 1.19T
+3.4% YoY
|
| EPS |
7.47
est: 9.37 (-20.3%)
|
9.06
est: 11.12 (-18.5%)
|
8.54
est: 8.42 (+1.5%)
|
1.24
est: 2.57 (-51.8%)
|
-25.60
est: 5.00 (-611.9%)
|
8.94
est: 0.20 (+4,269.5%)
|
52.12
est: 50.57 (+3.1%)
|
70.74
est: 45.14 (+56.7%)
|
93.27
est: 78.69 (+18.5%)
|
69.49
est: 87.59 (-20.7%)
|
85.68
est: 78.82 (+8.7%)
|
89.47
66.46 – 106.57
+13.5% YoY
|
101.70
70.56 – 141.14
+13.7% YoY
|
98.14
51.25 – 179.35
-3.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-26 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-25 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-05 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-04 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-15 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| David Utama | President Director | — | male |
| Mochtar Riady | Founder | — | — |
| Paulus Sujono | Hospital Chief Executive Officer | — | — |
| Ratih Hadiwinoto | Corporate Secretary | — | female |
| Wily Tjandera | Investor Relations Manager | — | — |
| Yuke Yolan Gunawan | Head of Internal Audit | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SILO.JK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
